Can OncoSil’s Device Safely Extend Life in Unresectable Pancreatic Cancer?
OncoSil Medical’s interim OSPREY registry data reveals promising survival improvements for patients with unresectable locally advanced pancreatic cancer treated with OncoSil™ plus chemotherapy. The findings suggest a meaningful step forward in a field with limited effective options.
- First interim analysis of 64 patients treated with OncoSil™ plus gemcitabine chemotherapy
- Median overall survival of 20.6 to 22.0 months in first-line patients, surpassing historical chemotherapy outcomes
- Low incidence of mild adverse device events with no serious complications reported
- Data submitted for presentation at ESGE Days 2026 in Milan
- Supports previous clinical trials and real-world evidence of OncoSil’s survival benefit
Encouraging Survival Outcomes in a Challenging Cancer
OncoSil Medical Limited has released interim results from its OSPREY registry, a real-world clinical study tracking patients with unresectable locally advanced pancreatic cancer (LAPC) treated with the OncoSil™ device alongside standard gemcitabine-based chemotherapy. The data, drawn from 64 patients across 19 European centres, shows median overall survival ranging from 20.6 to 22.0 months in first-line patients. This is a notable improvement compared to historical survival medians of 12.7 to 18.8 months for chemotherapy alone in similar patient populations.
A Safer, More Targeted Approach
The OncoSil™ device delivers targeted radiation via phosphorus-32 microparticles directly into the tumour, allowing higher local doses while sparing surrounding healthy tissue. Safety data from the registry is reassuring, with only 15.6% of patients experiencing mild adverse device events and no serious complications such as pancreatitis or hospital admissions. This safety profile aligns with previous clinical trials and supports OncoSil’s promise as a manageable adjunct to chemotherapy.
Bridging Clinical Trials and Real-World Practice
The OSPREY findings complement earlier studies including the PanCO trial and the PANCOSIL Phase 1-2 study, which also demonstrated extended survival and tolerability. The registry’s real-world setting adds valuable evidence that OncoSil’s benefits translate beyond controlled trial environments. Additionally, a propensity score analysis cited by the company indicates a significant survival advantage over chemotherapy alone, reinforcing the clinical relevance of this approach.
Looking Ahead to ESGE Days 2026
OncoSil Medical has submitted these interim results for presentation at the European Society of Gastrointestinal Endoscopy (ESGE) Days congress in Milan next May. This platform will provide an opportunity for broader clinical scrutiny and discussion among endoscopists and oncology specialists. Given the limited treatment options and poor prognosis historically associated with unresectable LAPC, these data could influence future therapeutic strategies and patient management.
Commercial and Regulatory Momentum
OncoSil is already approved in over 30 countries including the EU and UK, with commercial use underway in several European nations. The positive interim data from OSPREY may bolster confidence among clinicians and payers, potentially accelerating adoption. However, as the data is interim and observational, further follow-up and randomized studies will be important to confirm long-term benefits and safety across diverse patient groups.
Bottom Line?
OncoSil’s interim registry data offers a promising glimpse of improved survival in a tough cancer, but the oncology community awaits full results and broader validation.
Questions in the middle?
- Will longer-term follow-up from OSPREY confirm sustained survival benefits?
- How will OncoSil’s real-world safety profile compare as patient numbers grow?
- What impact will ESGE Days 2026 presentation have on clinical adoption and reimbursement?
